Study to Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

Inclusion Criteria:

1. Sign informed consent

2. Expected survival > or = 3months

3. Has histologically documented, incurable, locally advanced or metastatic epithelialorigin malignant cancer, priority to include the following tumor types: Non-SmallCell Lung Cancer, HER2- breast cancer, esophageal cancer, Small Cell Lung Cancer,and Nasopharyngeal Cancer

4. Agree to provide a tumor sample

5. Has at least one measurable lesion based on RECIST 1.1

6. Has an Eastern Cooperative Oncology Group performance status (ECOG PS) 0 to 1

7. Toxicity of previous antitumor therapy has returned to level ≤1 as defined byNCI-CTCAE V5.0 (except for asymptomatic laboratory abnormalities such as elevatedALP, hyperuricemia, elevated serum or plasma amylase/lipase, and elevated bloodglucose; except for toxicity that the investigator determined to have no safetyrisk, such as alopecia, grade 2 peripheral neurotoxicity, hypothyroidism stabilizedby hormone replacement therapy, etc.)

8. Has no serious cardiac dysfunction, left ventricular ejection fraction ≥50%.

9. Has adequate organ function before registration

10. Coagulation function: international normalized ratio (INR) ≤1.5×ULN, and activatedpartial thromboplastin time (APTT) ≤1.5 ULN

11. Urinary protein ≤2+ or ≤1000mg/24 hours

12. For premenopausal women with childbearing potential, a pregnancy test must be takenwithin 7 days prior to the start of treatment. Serum or urine pregnancy must benegative and must be non-lactating

13. Must agree to use adequate barrier contraceptive measures during the treatment and 6months after the end of treatment for all subjects (regardless of gender)

Exclusion Criteria:

1. Chemotherapy, biological therapy, immunotherapy, radical radiotherapy, majorsurgery, targeted therapy and other anti-tumor therapy within 4 weeks or 5half-lives (whichever is shorter) prior to the first administration

2. Subjects with history of severe heart disease

3. Active autoimmune diseases and inflammatory diseases

4. Other malignant tumors were diagnosed within 5 years

5. Subjects with poorly controlled hypertension

6. Subjects have Grade 3 lung disease or a history of interstitial lung disease

7. Unstable thrombotic events such as deep vein thrombosis, arterial thrombosis, andpulmonary embolism requiring therapeutic intervention within the previous 6 monthsbefore screening

8. Symptoms of active central nervous system metastasis

9. Subjects who have a history of allergies to recombinant humanized antibodies orhuman mouse chimeric antibodies or any of the components of BL-B01D1

10. Subjects have a history of autologous or allogeneic stem cell transplantation

11. Known HIV, active tuberculosis, active Hepatitis B virus infection or activeHepatitis C virus infection

12. Subjects with active infections requiring systemic treatment

13. Participated in another clinical trial within 4 weeks prior to participating in thestudy

14. Other conditions that the investigator believes that it is not suitable forparticipating in this clinical trial

15. Subjects with prolonged QT interval (QTc >470 msec), complete left bundle branchblock, Grade 3 atrioventricular block

16. Has received treatment with anthracyclines with a cumulative dose exceeding 360mg/m2